Faculty introduction, disclosures

Introductory content: cursory refresher and review ALL: estimated new cases by age distribution ALL outcomes in pediatric populations Staging and risk assessment Morphology, classification, and prognostic indicators Treatment outcome by minimum residual disease group Advances in molecular biology and impact on diagnosis – biomarker review and updates

Pediatric ALL management NCCN-recommended principles of pediatric treatment approaches Induction chemotherapy, consolidation therapy, and relapsed/refractory disease Limitations of cytotoxic chemotherapy Role for hematopoietic stem cell transplant Treatment for patients with detectable MRD postinduction or postreinduction Clinical trial Chemotherapy Bispecific antibody CAR-T therapy Treatment for relapsed disease Clinical trial Chemotherapy regimens Bispecific antibody CAR-T therapy Off-label antibody-drug conjugate Considerations for Ph+ ALL TKIs to consider Treatment for TKI intolerant or refractory Additional considerations: optimizing and managing asparaginase therapy Supportive care and patient/parent education Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Identify factors affecting the diagnosis, staging, and prognosis of children and adolescents with ALL.
• Develop pediatric ALL treatment strategies based on the most up-to-date clinical trial findings.
• Describe the risk-benefit calculus of ALL management strategies and apply them to patient cases, taking into account disease stage, prior treatment, past medical history, and prognostic indicators including detectable MRD.
• Evaluate a treatment plan, making modifications if necessary, for a patient with ALL based on initial treatment response and the presence of MRD.

ACCME Activity #202333861

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Joseph Rosenthal, MD, Barron Hilton Professor and Chair in Pediatrics, Director, Pediatric Hematology/Oncology, City of Hope National Medical Center, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version